EW STOCK FORECAST: After giving 40% returns to investors over 1 year, will the mometum continue in 2022?

EW Stock Forecast: For the Next 24 hours, the stock price of EW is predicted to trade between $ 115.94 and $ 122.70. The Overall recommendation for next 24 hours is buy.
2 of 3 momentum indicators are positive

EW is trading 2.13% higher at $ 122.12 in the last trading session.

Metric	Value
Market Cap	7.6 B
Share Volume	6M
Average Share Volume	2 M
Forward PE (1year)	52.91

Table of Contents

EW Stock Forecast: Momentum Summary

Metric	Indicator
Price	Higher
Technical indicators	Buy
Sentiment	NA

EW Stock Forecast: Performance Chart

	1 Day	5 Days	1 month	1 year
EW Stock	2.13%	0.24%	4.35%	42.60%

EW Stock Forecast: Technical Analysis

Analyst	S3	R1	Recommendation
Investing.com	114.52	121.76	Buy
Barchart.com	117.37	123.65	Buy

EW Stock Forecast: Latest Videos

Edwards Lifesciences CEO on outlook for 2022: ‘We are just getting started’

EW Stock Forecast: Sentiment Analysis

Day	Positive	Negative	Indicator
Day 7	0%	6%	Negative
Day 1	NA	NA	NA

EW Stock Forecast: Latest News and Tweets

vig.io on Twitter: “$EW is on the move: +1.74%⁣⁣Edwards Lifesciences shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and announced a $140 price target. / Twitter”
EW is on the move: +1.74%⁣⁣Edwards Lifesciences shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and announced a $140 price target.

Ew Healthcare Partners Fund 2, Buys 5,050 Shares of TELA Bio, Inc. (NASDAQ:TELA) Stock

EW Stock Forecast: Company Background

Edward lifesciences is an American based medical technology company. It was founded in the year 1958 in Irvine, California. The company works on Artificial heart valves and hemodynamic monitoring and produces new technologies to treat late cardiovascular diseases. It was founded by an engineer Miles Lowell Edwards.

EW Stock Forecast: Q3 Results

Sales increased 15% to 1.3 billion as of on 30^th September
Increased 15% in TAVR sales
Increased in US TAVR sales by 12% and OUS approximately 20%
Full year 2021 sales guidance range changed
EW reported that TAVR sales are $858 million in this third quarter of the financial year
With 7% increase compared to third quarter of the last year surgical structural heart sales were $217 million
The adjusted gross profit margin was 76.3% compared to 75.5% in the third quarter of last financial year.
Research and development expenses were $238 million by an increase of 22%
Free cash flow was $471 million and cash flow from operating activities is $532 million

-Rakesh Atla